GRAIL vs Veradermics
GRAIL (GRAL), health care, and Veradermics (MANE), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Veradermics is worth $5.3B on the stock market and GRAIL $4.8B: Veradermics is valued at 11% more. Over the past year GRAIL's share price has moved +29.6% and Veradermics's +239%.
Key facts
- GRAIL market value
- $4.8B
- Veradermics market value
- $5.3B
- GRAIL revenue
- $147.2MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | GRAIL | Veradermics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $4.8Blower | $5.3Bhigher |
| Revenue | $147.2M | — |
| Earnings | -$408.4Mlower | -$70Mhigher |
| Employees | 910higher | 37lower |
| Total assets | $2.9Bhigher | $152.6Mlower |
| Valuation | ||
| P/E | — | — |
| P/S | 32.3 | — |
| P/B | 1.9lower | 6.7higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | -382% | — |
| Balance sheet | ||
| Net assets | $2.6Bhigher | -$121Mlower |
| Total liabilities | $344.2Mhigher | $9.2Mlower |
| Total debt | — | — |
| Cash on hand | $249.7Mhigher | $21.8Mlower |
| Price change | ||
| Today | +0.27%higher | -1.88%lower |
| 1 year | +29.6%lower | +239%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
GRAIL only (3)
- Andrew Spokes3.0%
- Julian and Felix Baker1.4%
- Primecap team0.2%
Veradermics only (2)
- Lee Ainslie0.9%
- Andreas Halvorsen0.5%
Percentages are each holding's share of that investor's reported portfolio. Who owns GRAL · Who owns MANE
More on GRAIL
Further comparisons
GRAIL against its closest peers
Veradermics against its closest peers
Learn
Questions and answers
Which is bigger, GRAIL or Veradermics?
By market value, Veradermics is the larger: $5.3B against $4.8B for GRAIL.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both GRAIL and Veradermics?
None of the tracked superinvestors holds both in their latest 13F filing. 3 hold GRAIL and 2 hold Veradermics.
Cite this page
Funkfolio, “GRAIL vs Veradermics”, data as of 18 November 2026. https://funkfolio.com/compare/gral-vs-mane
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.